<DOC>
	<DOCNO>NCT01951625</DOCNO>
	<brief_summary>Objective study find optimal dose daily oral soluble guanylate cyclase stimulator ( sGC ) BAY1021189 Phase III give addition standard therapy heart failure reduce ejection fraction ( HFrEF ) .</brief_summary>
	<brief_title>Phase IIb Safety Efficacy Study Four Dose Regimens BAY1021189 Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure ( SOCRATES-REDUCED )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Worsening chronic heart failure ( WCHF ) require hospitalization ( intravenous diuretic treatment HF without hospitalization ) initiation study treatment clinical stabilization Left ventricular ejection fraction ( LVEF ) &lt; 45 % echocardiography randomization Intravenous inotropes time hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Worsening Heart Failure</keyword>
	<keyword>Heart Failure Reduced Ejection Fraction</keyword>
</DOC>